ContraFect Corporation
| NASDAQ: CFRX | Healthcare / Biotechnology / USA |
| 1.98 | -0.0201 | -1.00% | Vol 26.51K | 1Y Perf -46.52% |
| Mar 22nd, 2023 12:57 DELAYED |
| BID | 1.95 | ASK | 1.98 | ||
| Open | 2.00 | Previous Close | 2.00 | ||
| Pre-Market | 2.09 | After-Market | - | ||
| 0.09 4.50% | - - |
| Target Price | 3.67 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 85.36 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.06 | Earnings Rating | Strong Sell | |
| Market Cap | 2.57M | Earnings Date | 23rd Mar 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.21 | |
| Beta | 0.56 |
Today's Price Range 1.942.00 | 52W Range 1.75363.20 | 5 Year PE Ratio Range -3.40-2.90 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.31% | ||
| 1 Month | -37.89% | ||
| 3 Months | 1 904.01% | ||
| 6 Months | 937.88% | ||
| 1 Year | -46.52% | ||
| 3 Years | -69.37% | ||
| 5 Years | -89.74% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -60.82 | |||
ROE last 12 Months | -285.71 | |||
ROA (5Y Avg) | -15.72 | |||
ROA last 12 Months | -134.22 | |||
ROC (5Y Avg) | -108.29 | |||
ROC last 12 Months | -212.65 | |||
Return on invested Capital Q | -215.61 | |||
Return on invested Capital Y | -8.10 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| 0.44 | ||||
| - | ||||
| - | ||||
| -0.10 | ||||
| -1.13 | ||||
| -1.43 | ||||
| -0.07 | ||||
| -10 221 100.00 | ||||
| Forward PE | -1.56 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.70 | ||||
| 0.80 | ||||
| 0.16 | ||||
| 0.24 | ||||
| - | ||||
| Leverage Ratio | 3.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -18.40 | -34.40 | -86.96 |
| Q02 2022 | -23.20 | -36.80 | -58.62 |
| Q01 2022 | -26.40 | -40.80 | -54.55 |
| Q04 2021 | -19.20 | -8.80 | 54.17 |
| Q03 2021 | -20.80 | -10.40 | 50.00 |
| Q02 2021 | -0.22 | -0.27 | -22.73 |
| Q01 2021 | -0.26 | -0.18 | 30.77 |
| Q04 2020 | -0.28 | -0.52 | -85.71 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.29 | -52.63 | Negative |
| 12/2022 QR | -0.19 | 17.39 | Positive |
| 12/2022 FY | -1.50 | -11.94 | Negative |
| 12/2023 FY | -1.22 | -7.02 | Negative |
| Next Report Date | 23rd Mar 2023 |
| Estimated EPS Next Report | -27.20 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 26.51K |
| Shares Outstanding | 1.30K |
| Shares Float | 27.93M |
| Trades Count | 134 |
| Dollar Volume | 52.10K |
| Avg. Volume | 3.89M |
| Avg. Weekly Volume | 116.88K |
| Avg. Monthly Volume | 1.54M |
| Avg. Quarterly Volume | 10.02M |
ContraFect Corporation (NASDAQ: CFRX) stock closed at 2 per share at the end of the most recent trading day (a 11.73% change compared to the prior day closing price) with a volume of 152.28K shares and market capitalization of 2.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. ContraFect Corporation CEO is Roger J. Pomerantz.
The one-year performance of ContraFect Corporation stock is -46.52%, while year-to-date (YTD) performance is 1983.33%. CFRX stock has a five-year performance of -89.74%. Its 52-week range is between 1.75 and 363.2, which gives CFRX stock a 52-week price range ratio of 0.06%
ContraFect Corporation currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.44, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -134.22%, a ROC of -212.65% and a ROE of -285.71%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from ContraFect Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-27.20 for the next earnings report. ContraFect Corporation’s next earnings report date is 23rd Mar 2023.
The consensus rating of Wall Street analysts for ContraFect Corporation is Moderate Buy (2), with a target price of $3.67, which is +85.36% compared to the current price. The earnings rating for ContraFect Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ContraFect Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ContraFect Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.64, ATR14 : 0.43, CCI20 : -87.74, Chaikin Money Flow : -0.80, MACD : 0.06, Money Flow Index : 22.77, ROC : -36.51, RSI : 47.88, STOCH (14,3) : 15.72, STOCH RSI : 0.58, UO : 41.55, Williams %R : -84.28), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ContraFect Corporation in the last 12-months were:
ContraFect Corporation
ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.
CEO: Roger J. Pomerantz
Telephone: +1 914 207-2300
Address: 28 Wells Avenue, Yonkers 10701, NY, US
Number of employees: 24
